Global Oncology Academy
Popular
Jenny Seligmann, MBChB, PhD
Fortunato Ciardiello, MD, PhD
- NEW EPISODEMinuteCE®
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
1.00 program creditFortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
- NEW EPISODEMinuteCE®
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
1.00 program creditFortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Elizabeth R. Plimack, MD, MS, FASCO
Shilpa Gupta, MD
- Project Oncology®
Advancing Multiple Myeloma Treatment: The Role of Immunotherapy and Personalized Care
Shaji K. Kumar, MD
Elizabeth R. Plimack, MD, MS, FASCO
Medical News
medicalxpress.com
01/08/2025- sciencedaily.com
01/08/2025
- Medical NewsNew Technology Reverts Colon Cancer Cells to Normal-Like State Without Traditional Side Effectsnews-medical.net
01/08/2025
- news.uthscsa.edu
01/07/2025
CME/CE
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS, FASCO
Evan Y. Yu, MD
Elizabeth R. Plimack, MD, MS, FASCO
Lillibeth Velasco, MSN, RN
Elizabeth R. Plimack, MD, MS, FASCO
Lillibeth Velasco, MSN, RN
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Clinical Practice
- NEW EPISODEMinuteCE®
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
1.00 program creditFortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
- Clinician's Roundtable
Etranacogene Dezaparvovec for Hemophilia B: Efficacy and Safety Four Years Post-Infusion
Brian P. McDonough, MD, FAAFP
Guy Young, MD
Charles Turck, PharmD, BCPS, BCCCP
Anthony Stein, MD
Programs
- NEW EPISODEMinuteCE®
From Guidelines to Practice: First-Line Treatment Choices in mCRC
1.00 program creditFortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Peter Buch, MD, FACG, AGAF, FACP
Aasma Shaukat, MD, MPH
Brian P. McDonough, MD, FAAFP
John Mascarenhas, MD
Lucia Masarova, MD